Hikma wins dismissal of Takeda patent lawsuit over gout drug
Saturday, May 21, 2016
A federal court has cleared the way for Hikma Pharmaceuticals Plc to continue selling a drug with the same active chemical as Takeda Pharmaceutical Co's gout drug Colcrys, dismissing a patent lawsuit Takeda filed in an effort to keep the drug off the market.
U.S. District Judge Sue Robinson in Delaware ruled Wednesday that London-based Hikma does not induce doctors to infringe Japan-based Takeda's patents by selling its drug Mitigare, because Mitigare is not indicated for the uses covered by Takeda's patents.
Source : reuters.com
